Given the survival benefits conferred by T-DM1 in previously treated MBC [6–8], the phase III MARIANNE study sought to explore the efficacy and safety of T-DM1 in patients with previously untreated HER2-positive advanced breast cancer [9]. The gene discussed is ERBB2; the disease is breast carcinoma.